GENESIS THERAPEUTICS
Live / Allowed — Fourth extension granted (statement of use) (as of 31 Jul 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 09 Feb 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97259016
- Mark type
- Word mark
- Filed
- 09 Feb 2022
- Published for opposition
- 02 Jul 2024
- Attorney of record
- EMILIA F. CANNELLA
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological diseases and disorders; Pharmaceutical preparations for the treatment of rare autoimmune and immune-system-related diseases and disorders; all of the foregoing excluding preparations for the treatment of ocular and opthalmic diseases and disorders
Owner
- GENESIS MOLECULAR AI, INC., San Diego, CA, US
- Genesis Therapeutics, Inc., Burlingame, CA, US
- Genesis Therapeutics, Inc., Burlingame, CA, US
Board proceedings on this mark
- Ex Parte Appeal No. 97259016 — Genesis Therapeutics, Inc., filed 24 May 2024 (Terminated)
Prosecution history
- 01 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Jul 2026 — SOU EXTENSION 4 GRANTED
- 31 Jul 2026 — SOU EXTENSION 4 FILED
- 31 Jul 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Jun 2026 — SOU EXTENSION 3 GRANTED
- 04 Feb 2026 — SOU EXTENSION 3 FILED
- 18 Jun 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Feb 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 05 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 14 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Aug 2025 — SOU EXTENSION 2 GRANTED
- 13 Aug 2025 — SOU EXTENSION 2 FILED
- 13 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED